Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ziad A Massy

Showing results (1-10 of 453) with videos related to

Pageof 46
Sort By:
Kidney International|March 4, 2014
The author repliesZiad A Massy
Clinical and Experimental Nephrology|September 28, 2013
The role of lipids and uremic toxins in cardiovascular disease in CKDZiad A Massy
Kidney International. Supplement|April 16, 2003
Potential strategies to normalize the levels of homocysteine in chronic renal failure patientsZiad A Massy
Nephrologie & Therapeutique|May 20, 2008
[Reverse epidemiology in chronic kidney disease: beyond traditional explanations]Ziad A Massy
Seminars in Nephrology|January 18, 2006
Therapy of hyperhomocysteinemia in chronic kidney diseaseZiad A Massy
Kidney International|March 18, 2026
The management of chronic kidney disease-associated cardiovascular complications should go beyond the management of traditional cardiovascular risk factorsZiad A Massy
Kidney International|January 29, 2021
Hyponatremia under MAP kinase inhibitors: a complex relationship between aquaporins and ERK activationFlorence Assan, Ziad A Massy
Presse Medicale (Paris, France : 1983)|November 4, 2004
[The interest of statins in nephrology]Ziad A Massy, Michel Andréjak
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 4, 2018
From old uraemic toxins to new uraemic toxins: place of 'omics'Ziad A Massy, Sophie Liabeuf
Contributions to Nephrology|September 15, 2017
Middle-Molecule Uremic Toxins and Outcomes in Chronic Kidney DiseaseZiad A Massy, Sophie Liabeuf
Pageof 46

Showing results (1-10 of 453) with videos related to

Sort By:
Pageof 46
Kidney International|March 4, 2014
The author repliesZiad A Massy
Clinical and Experimental Nephrology|September 28, 2013
The role of lipids and uremic toxins in cardiovascular disease in CKDZiad A Massy
Kidney International. Supplement|April 16, 2003
Potential strategies to normalize the levels of homocysteine in chronic renal failure patientsZiad A Massy
Nephrologie & Therapeutique|May 20, 2008
[Reverse epidemiology in chronic kidney disease: beyond traditional explanations]Ziad A Massy
Seminars in Nephrology|January 18, 2006
Therapy of hyperhomocysteinemia in chronic kidney diseaseZiad A Massy
Kidney International|March 18, 2026
The management of chronic kidney disease-associated cardiovascular complications should go beyond the management of traditional cardiovascular risk factorsZiad A Massy
Kidney International|January 29, 2021
Hyponatremia under MAP kinase inhibitors: a complex relationship between aquaporins and ERK activationFlorence Assan, Ziad A Massy
Presse Medicale (Paris, France : 1983)|November 4, 2004
[The interest of statins in nephrology]Ziad A Massy, Michel Andréjak
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 4, 2018
From old uraemic toxins to new uraemic toxins: place of 'omics'Ziad A Massy, Sophie Liabeuf
Contributions to Nephrology|September 15, 2017
Middle-Molecule Uremic Toxins and Outcomes in Chronic Kidney DiseaseZiad A Massy, Sophie Liabeuf
Pageof 46